Michelle A Elliott MD
Hematologic Oncology
Associate Professor, Internal Medicine, Mayo Medical School
Join to View Full Profile
200 1st St SwRochester, MN 55905
Phone+1 507-284-2511
Dr. Elliott is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1995
University of Dublin Trinity CollegeClass of 1991, MB BCh
Certifications & Licensure
MN State Medical License 1994 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- 3 citationsMayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
American Journal of Hematology. 2025-02-01 - 1 citationsHigh-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.Zhuoer Xie, Jenna Fernandez, Terra Lasho, Christy Finke, Michelle Amundson
Blood. 2024-12-05 - 4 citationsAspirin therapy is associated with a lower risk of pregnancy loss in both JAK2- and CALR-mutated essential thrombocythemia-A Mayo Clinic study of 200 pregnancies.Naseema Gangat, Amritpal Singh, Rimal Ilyas, Giuseppe Gaetano Loscocco, Michelle Elliott
American Journal of Hematology. 2024-10-01
Abstracts/Posters
- Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be BeneficialMichelle A Elliott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition SyndromesMichelle A Elliott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International CollaborationMichelle A Elliott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Authored Content
- Prognostic Impact of ASXL1 Mutations in Patients with Myelodysplastic Syndromes and Multilineage Dysplasia with or Without Ring SideroblastsJuly 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
